About Inotiv
Inotiv is a publicly listed company based in West Lafayette (United States) founded in 1974. Inotiv is engaged in providing drug discovery and development services. It operates on a Professional Services and Reseller / Distribution model. The company has 2,080 employees. Its chief executive, as recorded, is Robert Leasure Jr. Its website inotiv.com draws about 52 thousand monthly visits. Inotiv offers products and services including Discovery and Translational Sciences, Safety Assessment Toxicology, Research Models and Services, and Teklad Diet and Bedding. Its focus areas include Biotechnology and Contract Research Organizations. Its legal entity is Inotiv, Inc. Its competitors include Charles River Laboratories, Cytel and LabCorp; 1 of its 3 listed competitors has raised funding.
Company details
Inotiv is involved in offering a wide range of nonclinical and analytical services from drug discovery through clinical development. Services are provided across various therapeutic areas including cardiovascular, oncology, and neuroscience. Research models and related support services are supplied to pharmaceutical, biotech, government, and academic organizations. Solutions are tailored for different research phases such as discovery, IND-enabling, and pre-marketing authorization. Additionally, animal care products like diets and bedding are distributed under the Teklad brand to ensure consistent research outcomes.
- Headquarters West Lafayette, United States
- Employees 2,080
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website inotiv.com
- Social LinkedIn X
- Legal Name Inotiv, Inc.
- Annual Revenue$513.02 M (USD)4.54as on Sep 30, 2025
- Net Profit-$68.63 M (USD)36.72as on Sep 30, 2025
- EBITDA$21.21 M (USD)189.07as on Sep 30, 2025
- Latest Funding Round$150K (USD), Grant
Sep 2018
- Investors
- Employee Count2,080
Products & Services of Inotiv
Inotiv offers a comprehensive portfolio of products and services, including Discovery and Translational Sciences, Safety Assessment Toxicology, Research Models and Services, and Teklad Diet and Bedding.
Services are provided for early drug discovery research.
Toxicology studies are conducted for safety evaluation purposes.
Models and services are offered for research purposes.
Diets and bedding are supplied for research animals.
Funding Insights of Inotiv
- Total Rounds 1
- Last Round Grant — $149,999
- First Round $149,999
(Sep 2018)
- Investors Count 1
All 1 funding rounds of Inotiv with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | $149,999 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Inotiv
Inotiv has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Inotiv
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Inotiv
1 people are tracked at Inotiv (1 in leadership); the tracked headcount is 2,080.
| Name | Role | Group |
|---|---|---|
Robert Leasure Jr | CEO & President | Leadership |
Complete people profiles for Inotiv
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Inotiv
Inotiv is a publicly listed company on the NASDAQ with ticker symbol NOTV in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Nov 1997
- Listed onNASDAQ: NOTV
- Listed entityInotiv, Inc.
- Exchange sectorCommercial services
- ISINUS45783Q1004
- Share price$0.30 (+3.37% on the day) · 2026-05-11
- Market capitalisation$10.5M
- EPS (diluted, trailing year)$-2.02
- Volume (last session)323,509
- Analyst consensusStrong buy
Financials of Inotiv
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $513.0M | -$68.6M | $21.2M |
| 2024 | $490.7M | -$108.4M | $7.3M |
| 2023 | $572.4M | -$105.1M | $52.3M |
| 2022 | $547.7M | -$337.0M | $52.2M |
| 2021 | $89.6M | $10.9M | $9.1M |
Detailed financial statements for Inotiv
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Inotiv
3 dated milestones of Inotiv across 44 years, from founding to its latest funding, stage changes and deals.
- Founded Inotiv is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $150K.
Competitors of Inotiv
Inotiv has 3 listed competitors in our database, 1 of them funded. They include Charles River Laboratories, Cytel and LabCorp.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| criver.com | 1947 | Wilmington, United States | 21,400 | Provider of drug discovery and preclinical development services | ||
| cytel.com | 1987 | Cambridge, United States | $2M | 509 | Data analysis and statistical solutions are provided for life sciences. | |
| labcorp.com | 1969 | Burlington, United States | 9,321 | Provider of laboratory tests for physicians |
Detailed competitors of Inotiv
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Inotiv
The website of Inotiv (inotiv.com) receives about 51.7K visits a month.
- Monthly visits51.7K
▲ 22.3% vs previous month
Websites whose visitors overlap most with Inotiv. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| taconic.com | 100% | 49.8K | #707,498 | View details | |
| clinisciences.com | 93% | 680.7K | #386,034 | View details | |
| criver.com | 93% | 224.6K | #186,811 | View details | |
| frontagelab.com | 79% | 10.4K | #2,115,173 | View details | |
| basinc.com | 60% | 19.7K | #1,425,894 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Inotiv (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inotiv
Complete news archive for Inotiv
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inotiv
Inotiv was founded in 1974 and raised its 1st funding round 44 years after it was founded.
Inotiv is headquartered in West Lafayette, United States. It is registered at West Lafayette, Indiana, United States.
Robert Leasure Jr is the CEO of Inotiv, as recorded in our data.
Inotiv has 2,080 employees.
Annual revenue of Inotiv is $513.02M as on Sep 30, 2025.
Inotiv is involved in offering a wide range of nonclinical and analytical services from drug discovery through clinical development. Services are provided across various therapeutic areas including cardiovascular, oncology, and neuroscience. Research models and related support services are supplied to pharmaceutical, biotech, government, and academic organizations. Solutions are tailored for different research phases such as discovery, IND-enabling, and pre-marketing authorization. Additionally, animal care products like diets and bedding are distributed under the Teklad brand to ensure consistent research outcomes.
Inotiv's top competitors include LabCorp, Charles River Laboratories and Cytel.
Inotiv offers Discovery and Translational Sciences, Safety Assessment Toxicology, Research Models and Services, and Teklad Diet and Bedding.
Yes, Inotiv is publicly traded on NASDAQ under the ticker symbol NOTV.
Inotiv has 1 investor. Key investors include HHS.
Inotiv operates through Inotiv, Inc..